Forcyte Biotechnologies, Inc

the function-first biology company

Forcyte awarded NIH funding for a FLECS-based uterine contractility model

Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to develop a FLECS-based assay focusing on uterine contractility that will enable deeper functional studies on reproductive disorders.

Scroll to Top